Summary

The mRNA synthesis and manufacturing market is expected to reach USD 738.3 million in 2029 from USD 624.4 million in 2024, at a CAGR of 3.4% during the forecast period. mRNA therapeutics hold promise as the next generation of drugs for tissue restoration in regenerative medicine. The development of non-immunogenic mRNA can be achieved through the use of modified nucleosides, which enhances safety and efficacy. By altering the mRNA structure, researchers can create stable, non-immunogenic mRNA through in vitro transcription. Furthermore, effective delivery strategies tailored specifically for mRNA are crucial for the advancement of these therapies. The processes involved in loading and releasing mRNA from biomaterials are essential for their application in tissue restoration and require further refinement to maximize their potential.
“The transcription consumables segment accounted for the largest share by product segment in the mRNA synthesis and manufacturing market in 2023.”
Based on product, the mRNA synthesis and manufacturing market is segmented into consumables, and instrument. In 2023, the consumables segment accounted for the largest share of mRNA synthesis and manufacturing market; this segment is further segmented into transcription consumables, purification consumables, and analysis & characterization consumables. Dominance of the consumables segment throughout the forecast period is attributed to the fact that they are essential for mRNA synthesis and manufacturing. Unlike instruments, which are a one-time investment, consumables must be replenished regularly, leading to continuous demand. Also, the entire market operates majorly on instruments offered by Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), whereas more companies operate in the consumables space for mRNA synthesis and manufacturing.

“The mRNA synthesis & modification service segment is expected to grow at the highest growth rate in the mRNA synthesis and manufacturing market throughout the forecast period.”
Based on service, the mRNA synthesis and manufacturing market is segmented into mRNA synthesis & modification, mRNA purification, mRNA analysis & characterization, and manufacturing & scale-up. In 2023, the mRNA synthesis & modification segment accounted for the largest share of the mRNA synthesis and manufacturing market. A significant driver for the mRNA synthesis and modification services within the mRNA synthesis and manufacturing market is the growing need for customized mRNA sequences and modifications to enhance the efficacy and stability of therapeutic and vaccine candidates, which requires specialized synthesis and modification services. As the application of mRNA technology expands, researchers and developers increasingly seek tailored mRNA sequences that can be optimized for specific therapeutic outcomes, such as improved protein expression or enhanced immune response.

“The Asia Pacific region is growing at the highest CAGR in the mRNA synthesis and manufacturing market from 2024 to 2029.”
The mRNA synthesis and manufacturing market is segmented into six major regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is the fastest-growing regional segment in the global mRNA synthesis and manufacturing market, Factors such as rising healthcare expenditure; growing R&D expansion in key markets such as India, China, and Japan; low labor costs; and the favorable regulatory environment in the region are expected to contribute to market growth. China's mRNA synthesis and manufacturing market is driven by the country’s substantial government investments in biotech innovation, rapid expansion of domestic biotech infrastructure, and increasing international collaborations. In recent developments, China has demonstrated a strong commitment to advancing mRNA technology.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20%
• By Designation: Directors - 50%, Managers - 30%, and Others - 20%
• By Region: North America -40%, Europe -35%, Asia-Pacific -20%, ROW -5%
List of Companies Profiled in the Report:
• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (US)
• GenScript (US)
• New England Biolabs (US)
• AldevronLLC. (Danaher Corporation) (US)
• Promega Corporation (US)
• Sartorius AG (Germany)
• WuXi Biologics (China)
• Takara Bio Inc. (Japan)
• GENEWIZ (Azenta USInc.) (US)
• TriLink BioTechnologies (US)
• Lonza (Switzerland)
• Telesis Bio Inc. (US)
• Aurigene Pharmaceutical Services Ltd. (Dr. Reddy’s Laboratories Ltd.) (India)
• ST Pharm (South Korea)AGC Biologics (US)

Research Coverage:
This research report categorizes the mRNA synthesis and manufacturing market by Product (transcription consumables, purification consumables, analysis & characterization consumables, and instrument), Application (cell and gene therapy, vaccine, and other applications), End User (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the mRNA synthesis and manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the mRNA synthesis and manufacturing market. Competitive analysis of top players and upcoming startups in the mRNA synthesis and manufacturing market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mRNA synthesis and manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Growing focus on mRNA-based vaccine development, expanding therapeutic applications of mrna technology, advancements in mrna synthesis technology, increased outsourcing for mrna synthesis and modification, and collaborations among industry players), restraints (High production cost, stringent regulations), opportunities (Advancements in drug delivery technologies, increased government funding and private investment, applications in regenerative medicines), and challenges (Stability, storage, and manufacturing scalability) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the mRNA synthesis and manufacturing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the mRNA synthesis and manufacturing market
• Competitive Assessment: Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), GenScript (US), New England Biolabs (US), Aldevron, LLC. (Danaher Corporation) (US), Promega Corporation (US), Sartorius AG (Germany), WuXi Biologics (China), Takara Bio Inc. (Japan), GENEWIZ (Azenta US, Inc.) (US), TriLink BioTechnologies (US), Lonza (Switzerland), Telesis Bio Inc. (US), Aurigene Pharmaceutical Services Ltd. (Dr. Reddy’s Laboratories Ltd.) (India), ST Pharm (South Korea), AGC Biologics (US), among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 34
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 35
1.3.2 INCLUSIONS AND EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.4 CURRENCY CONSIDERED 36
1.5 STAKEHOLDERS 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 38
2.1.2 PRIMARY DATA 39
2.2 MARKET SIZE ESTIMATION 41
2.2.1 GLOBAL MARKET SIZE ESTIMATION 42
2.2.2 INSIGHTS FROM PRIMARY SOURCES 45
2.2.3 TOP-DOWN APPROACH 45
2.3 GROWTH RATE PROJECTIONS 46
2.4 DATA TRIANGULATION 48
2.5 RESEARCH ASSUMPTIONS 49
2.6 RESEARCH LIMITATIONS 50
2.7 RISK ANALYSIS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 56
4.1 MRNA SYNTHESIS & MANUFACTURING MARKET OVERVIEW 56
4.2 NORTH AMERICA: MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT AND COUNTRY, 2023 57
4.3 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET: GLOBAL GROWTH OPPORTUNITIES 57
 
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
5.2.1 DRIVERS 59
5.2.1.1 Rise in clinical trials for mRNA vaccines 59
5.2.1.2 Continuous improvements in design, delivery systems, and manufacturing processes 60
5.2.1.3 Increased outsourcing of mRNA synthesis and production 61
5.2.1.4 Advantages of mRNA-based technology over recombinant expression 61
5.2.2 RESTRAINTS 62
5.2.2.1 High production cost 62
5.2.2.2 Stringent regulations 62
5.2.3 OPPORTUNITIES 63
5.2.3.1 Ongoing innovations in nanoparticles and cell-specific delivery technologies 63
5.2.3.2 Expanding applications of mRNA technology 63
5.2.3.3 Increased government funding and private investments 65
5.2.4 CHALLENGES 66
5.2.4.1 Stability, storage, and manufacturing scalability issues 66
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 66
5.4 REGULATORY LANDSCAPE 67
5.4.1 REGULATORY SCENARIO 67
5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
5.5 VALUE CHAIN ANALYSIS 71
5.6 TECHNOLOGY ANALYSIS 72
5.6.1 KEY TECHNOLOGIES 72
5.6.1.1 In vitro transcription 72
5.6.1.2 Poly(A) tail synthesis 73
5.6.1.3 RNA stabilization technologies 73
5.6.2 COMPLEMENTARY TECHNOLOGIES 73
5.6.2.1 Next-generation sequencing 73
5.6.2.2 Gene cloning and vector construction 74
5.6.2.3 DNA amplification 74
5.6.3 ADJACENT TECHNOLOGIES 74
5.6.3.1 Spectrophotometry 74
5.6.3.2 Electrophoresis 75
5.6.3.3 High-performance liquid chromatography 75
5.7 PRICING ANALYSIS 75
5.7.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY INSTRUMENT 76
5.7.2 AVERAGE SELLING PRICE TREND FOR CONSUMABLES 76
5.7.3 AVERAGE SELLING PRICE, BY REGION 77
5.8 PATENT ANALYSIS 78
5.9 SUPPLY CHAIN ANALYSIS 79
5.10 ECOSYSTEM ANALYSIS 81
5.11 KEY CONFERENCES AND EVENTS, 2024–2025 83
5.12 PORTER’S FIVE FORCES ANALYSIS 84
5.12.1 INTENSITY OF COMPETITIVE RIVALRY 85
5.12.2 BARGAINING POWER OF SUPPLIERS 85
5.12.3 BARGAINING POWER OF BUYERS 85
5.12.4 THREAT OF SUBSTITUTES 85
5.12.5 THREAT OF NEW ENTRANTS 86
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 86
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
5.13.2 KEY BUYING CRITERIA, BY END USER (PRODUCT) 87
5.14 INVESTMENT AND FUNDING SCENARIO 88
5.15 IMPACT OF AI ON MRNA SYNTHESIS & MANUFACTURING MARKET 88
6 MRNA SYNTHESIS & MANUFACTURING MARKET, BY PRODUCT 90
6.1 INTRODUCTION 91
6.2 CONSUMABLES 92
6.2.1 TRANSCRIPTION CONSUMABLES 94
6.2.1.1 mRNA synthesis kits 97
6.2.1.1.1 Increasing demand for rapid and efficient mRNA vaccine development to augment growth 97
6.2.1.2 mRNA profiling kits 99
6.2.1.2.1 Growing need for precision medicine and personalized therapies to propel market 99
6.2.1.3 RNA polymerases 101
6.2.1.3.1 Growing demand for high-quality and scalable mRNA production to boost market 101
6.2.1.4 Plasmid DNA/DNA templates 103
6.2.1.4.1 Rapid growth of mRNA-based therapeutics and vaccines to expedite growth 103
6.2.1.5 Nucleotides 105
6.2.1.5.1 Need to support diverse research & development initiatives to promote growth 105
6.2.1.6 Vectors 107
6.2.1.6.1 Need for reliable and high-capacity vectors to propel market 107
6.2.1.7 Other transcription consumables 109
 
6.2.2 PURIFICATION CONSUMABLES 111
6.2.2.1 Purification kits & reagents 114
6.2.2.1.1 Rising focus on quality assurance to encourage growth 114
6.2.2.2 Chromatography filters & membranes 116
6.2.2.2.1 Growing emphasis on process optimization and cost-efficiency in large-scale production to drive market 116
6.2.2.3 Other purification consumables 118
6.2.3 ANALYSIS & CHARACTERIZATION CONSUMABLES 120
6.2.3.1 Analysis kits & reagents 122
6.2.3.1.1 Emerging applications of mRNA beyond vaccines to support growth 122
6.2.3.2 Other analysis & characterization consumables 124
6.3 INSTRUMENTS 126
6.3.1 NEED TO REDUCE PRODUCTION COST AND HIGHER SCALABILITY TO PROMOTE GROWTH 126
7 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY APPLICATION 129
7.1 INTRODUCTION 130
7.2 CELL & GENE THERAPIES 130
7.2.1 RISING ADOPTION OF MRNA TECHNOLOGY TO TREAT GENETIC DISORDERS AND CANCER TO FUEL MARKET 130
7.3 VACCINES 132
7.3.1 INCREASING DEVELOPMENT AND DEPLOYMENT OF MRNA VACCINES TO ACCELERATE GROWTH 132
7.4 OTHER APPLICATIONS 134
8 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET, BY END USER 137
8.1 INTRODUCTION 138
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 138
8.2.1 NEED TO RESPOND TO EMERGING INFECTIOUS DISEASES TO DRIVE MARKET 138
8.3 ACADEMIC & RESEARCH INSTITUTIONS 141
8.3.1 INCREASING INVESTMENTS IN RESEARCH TO EXPEDITE GROWTH 141
8.4 CROS & CDMOS 143
8.4.1 RISING DEMAND FOR OUTSOURCED SERVICES TO AID GROWTH 143
9 MRNA SYNTHESIS & MANUFACTURING MARKET, BY SERVICE 146
9.1 INTRODUCTION 147
9.2 MRNA SYNTHESIS & MODIFICATION SERVICES 147
9.2.1 GROWING NEED FOR CUSTOMIZED MRNA SEQUENCES AND MODIFICATIONS TO FUEL MARKET 147
9.3 MRNA PURIFICATION SERVICES 149
9.3.1 NEED FOR PERSONALIZED MRNA VACCINES TO BOOST MARKET 149
9.4 MRNA ANALYSIS & CHARACTERIZATION SERVICES 151
9.4.1 INCREASING REGULATORY SCRUTINY TO EXPEDITE GROWTH 151
9.5 MANUFACTURING & SCALE-UP SERVICES 153
9.5.1 GROWING TRANSITION FROM SMALL-SCALE RESEARCH & DEVELOPMENT TO LARGE-SCALE COMMERCIAL PRODUCTION TO DRIVE MARKET 153
10 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET, BY END USER 156
10.1 INTRODUCTION 157
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 157
10.2.1 RAPID DEVELOPMENT AND COMMERCIALIZATION OF MRNA-BASED PRODUCTS TO ENCOURAGE GROWTH 157
10.3 ACADEMIC & RESEARCH INSTITUTIONS 160
10.3.1 INCREASING EMPHASIS ON TRANSLATING MRNA-BASED DISCOVERIES INTO PRACTICAL APPLICATIONS TO AID GROWTH 160
10.4 SMALL-SCALE CROS & CDMOS 162
10.4.1 NEED FOR SPECIALIZED AND FLEXIBLE PRODUCTION IN BIOTECH COMPANIES AND EARLY-STAGE MRNA PROJECTS TO BOOST MARKET 162
11 MRNA SYNTHESIS & MANUFACTURING MARKET, BY REGION 165
11.1 INTRODUCTION 166
11.2 NORTH AMERICA 167
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 171
11.2.2 US 172
11.2.2.1 Increasing demand for mRNA-based vaccines and therapeutics to accelerate growth 172
11.2.3 CANADA 176
11.2.3.1 Increasing collaborations between academic institutions and market players to spur growth 176
11.3 EUROPE 179
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 183
11.3.2 GERMANY 184
11.3.2.1 Growing establishment of manufacturing sites to boost market 184
11.3.3 UK 188
11.3.3.1 Presence of state-of-the-art facilities to support growth 188
11.3.4 FRANCE 191
11.3.4.1 Favorable government support for biopharmaceutical production to drive market 191
11.3.5 SWITZERLAND 195
11.3.5.1 Robust biotech sector and production facilities to promote growth 195
11.3.6 ITALY 198
11.3.6.1 Increasing collaborations among biotech firms and manufacturing facilities to aid growth 198
11.3.7 SPAIN 202
11.3.7.1 Growing investments in biotechnology to fuel market 202
11.3.8 REST OF EUROPE 205
 
11.4 ASIA PACIFIC 209
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 214
11.4.2 CHINA 214
11.4.2.1 Rapid expansion of domestic biotech sector to contribute to growth 214
11.4.3 JAPAN 218
11.4.3.1 Growing strategic investments in biotechnology infrastructure to boost market 218
11.4.4 INDIA 221
11.4.4.1 Booming biotech sector and international collaborations to augment growth 221
11.4.5 SOUTH KOREA 225
11.4.5.1 Increased government funding in research and vaccine development to bolster growth 225
11.4.6 REST OF ASIA PACIFIC 228
11.5 LATIN AMERICA 232
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 236
11.5.2 BRAZIL 237
11.5.2.1 Increased funding for strengthening infrastructure to sustain growth 237
11.5.3 REST OF LATIN AMERICA 240
11.6 MIDDLE EAST 243
11.6.1 GROWING INVESTMENTS FROM PRIVATE SECTOR AND ACADEMIC RESEARCH INITIATIVES TO DRIVE MARKET 243
11.6.2 MACROECONOMIC OUTLOOK IN MIDDLE EAST 247
11.7 AFRICA 248
11.7.1 GROWING INITIATIVES TO ENHANCE LOCAL PRODUCTION CAPABILITIES TO PROPEL MARKET 248
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 251
12 COMPETITIVE LANDSCAPE 252
12.1 INTRODUCTION 252
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021–AUGUST 2024 252
12.3 REVENUE ANALYSIS, 2019–2023 254
12.4 MARKET SHARE ANALYSIS, 2023 255
12.4.1 MRNA SYNTHESIS & MANUFACTURING PRODUCT MARKET 255
12.4.2 MRNA SYNTHESIS & MANUFACTURING SERVICE MARKET 256
12.5 COMPANY VALUATION AND FINANCIAL METRICS 257
12.6 BRAND/SERVICE COMPARISON 259
12.6.1 ALDEVRON LLC (DANAHER CORPORATION) (US) 259
12.6.2 THERMO FISHER SCIENTIFIC INC. (US) 260
12.6.3 TRILINK BIOTECHNOLOGIES (US) 260
12.6.4 LONZA (SWITZERLAND) 260
12.6.5 MERCK KGAA (GERMANY) 260
 
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 260
12.7.1 STARS 261
12.7.2 EMERGING LEADERS 261
12.7.3 PERVASIVE PLAYERS 261
12.7.4 PARTICIPANTS 261
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 263
12.7.5.1 Company footprint 263
12.7.5.2 Region footprint 263
12.7.5.3 Product footprint 264
12.7.5.4 Service footprint 265
12.7.5.5 Application footprint 266
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 267
12.8.1 PROGRESSIVE COMPANIES 267
12.8.2 RESPONSIVE COMPANIES 267
12.8.3 DYNAMIC COMPANIES 267
12.8.4 STARTING BLOCKS 267
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 268
12.8.5.1 Detailed list of key startups/SMEs 268
12.8.5.2 Competitive benchmarking of key startups/SMES 269
12.9 COMPETITIVE SCENARIO 270
12.9.1 PRODUCT/SERVICE LAUNCHES 270
12.9.2 DEALS 271
12.9.3 EXPANSIONS 271
13 COMPANY PROFILES 273
13.1 KEY PLAYERS 273
13.1.1 THERMO FISHER SCIENTIFIC INC. 273
13.1.1.1 Business overview 273
13.1.1.2 Products/Services offered 274
13.1.1.3 Recent developments 276
13.1.1.3.1 Product/Service launches 276
13.1.1.3.2 Deals 276
13.1.1.3.3 Expansions 276
13.1.1.4 MnM view 277
13.1.1.4.1 Key strengths 277
13.1.1.4.2 Strategic choices 277
13.1.1.4.3 Weaknesses and competitive threats 277
 
13.1.2 DANAHER CORPORATION 278
13.1.2.1 Business overview 278
13.1.2.2 Products/Services offered 279
13.1.2.3 Recent developments 281
13.1.2.3.1 Product/Service launches 281
13.1.2.3.2 Deals 281
13.1.2.3.3 Expansions 281
13.1.2.4 MnM view 282
13.1.2.4.1 Key strengths 282
13.1.2.4.2 Strategic choices 282
13.1.2.4.3 Weaknesses and competitive threats 282
13.1.3 MERCK KGAA 283
13.1.3.1 Business overview 283
13.1.3.2 Products/Services offered 284
13.1.3.3 Recent developments 287
13.1.3.3.1 Deals 287
13.1.3.3.2 Expansions 287
13.1.3.4 MnM view 288
13.1.3.4.1 Key strengths 288
13.1.3.4.2 Strategic choices 288
13.1.3.4.3 Weaknesses and competitive threats 288
13.1.4 LONZA 289
13.1.4.1 Business overview 289
13.1.4.2 Products/Services offered 290
13.1.4.3 Recent developments 291
13.1.4.3.1 Deals 291
13.1.4.3.2 Expansions 291
13.1.4.4 MnM view 292
13.1.4.4.1 Key strengths 292
13.1.4.4.2 Strategic choices 292
13.1.4.4.3 Weaknesses and competitive threats 292
13.1.5 MARVAI LIFESCIENCES 293
13.1.5.1 Business overview 293
13.1.5.2 Products/Services offered 294
13.1.5.3 Recent developments 297
13.1.5.3.1 Product/Service launches 297
13.1.5.3.2 Deals 297
13.1.5.3.3 Expansions 298
13.1.5.4 MnM view 298
13.1.5.4.1 Key strengths 298
13.1.5.4.2 Strategic choices 298
13.1.5.4.3 Weaknesses and competitive threats 298
13.1.6 NEW ENGLAND BIOLABS 299
13.1.6.1 Business overview 299
13.1.6.2 Products/Services offered 299
13.1.6.3 Recent developments 300
13.1.6.3.1 Product/Service launches 300
13.1.7 PROMEGA CORPORATION 301
13.1.7.1 Business overview 301
13.1.7.2 Products/Services offered 301
13.1.7.3 Recent developments 302
13.1.7.3.1 Expansions 302
13.1.7.3.2 Other developments 302
13.1.8 GENSCRIPT 303
13.1.8.1 Business overview 303
13.1.8.2 Products/Services offered 304
13.1.8.3 Recent developments 305
13.1.8.3.1 Product/Service launches 305
13.1.8.3.2 Deals 306
13.1.8.3.3 Expansions 306
13.1.8.4 MnM view 307
13.1.8.4.1 Key strengths 307
13.1.8.4.2 Strategic choices 307
13.1.8.4.3 Weaknesses and competitive threats 307
13.1.9 WUXI BIOLOGICS 308
13.1.9.1 Business overview 308
13.1.9.2 Products/Services offered 309
13.1.9.3 Recent developments 310
13.1.9.3.1 Expansions 310
13.1.10 TAKARA BIO INC. 311
13.1.10.1 Business overview 311
13.1.10.2 Products/Services offered 312
13.1.10.3 Recent developments 313
13.1.10.3.1 Product/Service launches 313
13.1.10.3.2 Deals 313
13.1.11 SARTORIUS AG 314
13.1.11.1 Business overview 314
13.1.11.2 Products/Services offered 315
13.1.11.3 Recent developments 316
13.1.11.3.1 Deals 316
13.1.12 GENEWIZ 317
13.1.12.1 Business overview 317
13.1.12.2 Products/Services offered 318
 
13.1.13 TELESIS BIO INC. 319
13.1.13.1 Business overview 319
13.1.13.2 Products/Services offered 320
13.1.13.3 Recent developments 321
13.1.13.3.1 Product/Service launches 321
13.1.13.3.2 Deals 321
13.1.14 ST PHARM 322
13.1.14.1 Business overview 322
13.1.14.2 Products/Services offered 323
13.1.14.3 Recent developments 323
13.1.14.3.1 Deals 323
13.1.15 AGC BIOLOGICS 324
13.1.15.1 Business overview 324
13.1.15.2 Products/Services offered 324
13.1.15.3 Recent developments 325
13.1.15.3.1 Deals 325
13.1.15.3.2 Expansions 325
13.1.16 DR. REDDY’S LABORATORIES LTD. 326
13.1.16.1 Business overview 326
13.1.16.2 Products/Services offered 327
13.1.16.3 Recent developments 327
13.1.16.3.1 Expansions 327
13.2 OTHER PLAYERS 328
13.2.1 ETHERNA 328
13.2.2 BOC SCIENCES 329
13.2.3 BIOMAY AG 330
13.2.4 CURIA GLOBAL, INC. 331
13.2.5 JENA BIOSCIENCE GMBH 332
13.2.6 ENZYNOMICS CO., LTD. 333
13.2.7 KANEKA EUROGENTEC S.A. 334
13.2.8 VERNAL BIOSCIENCES 334
13.2.9 CELLSCRIPT 335
14 APPENDIX 336
14.1 DISCUSSION GUIDE 336
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 340
14.3 CUSTOMIZATION OPTIONS 342
14.4 RELATED REPORTS 342
14.5 AUTHOR DETAILS 343